ViroPharma Talks Cinryze Sales, EU Launches
This article was originally published in The Pink Sheet Daily
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
You may also be interested in...
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.
Shire is snapping up ViroPharma at a hefty premium to secure possession of C1 esterase inhibitor Cinryze and position the group as a formidable force in treatments for rare diseases.
Some analysts balked, but Salix management defended the price the company is paying for Santarus on a Nov. 7 earnings call, arguing that synergies from an integration support the valuation of six to seven times the sales price.